Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jun 2

PMID 34073911

Citations 16

Authors

Veronika Mancikova

Michal Smida

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.

Citing Articles

Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.

Hatashima A, Shadman M, Raghunathan V Cancers (Basel). 2025; 17(2).

PMID: 39858050 PMC: 11763375. DOI: 10.3390/cancers17020268.

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.

Kandav G, Chandel A Med Oncol. 2024; 41(11):275.

PMID: 39400611 DOI: 10.1007/s12032-024-02491-6.

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures.

Majumder A Cancers (Basel). 2024; 16(1).

PMID: 38201467 PMC: 10777914. DOI: 10.3390/cancers16010039.

Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany.

Barate C, Sanna A, Benedetti E, Bocchia M, Capochiani E, Danesi R Clin Exp Med. 2023; 23(8):4251-4264.

PMID: 37979127 DOI: 10.1007/s10238-023-01244-5.

Depletion of polyfunctional CD26CD8 T cells repertoire in chronic lymphocytic leukemia.

Bozorgmehr N, Hnatiuk M, Peters A, Elahi S Exp Hematol Oncol. 2023; 12(1):13.

PMID: 36707896 PMC: 9881277. DOI: 10.1186/s40164-023-00375-5.

References

Ramos C, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O . Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016; 126(7):2588-96. PMC: 4922690. DOI: 10.1172/JCI86000. View

Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz P . Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res. 2014; 3(2):206-16. PMC: 4324006. DOI: 10.1158/2326-6066.CIR-14-0163. View

Nobles C, Sherrill-Mix S, Everett J, Reddy S, Fraietta J, Porter D . CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest. 2019; 130(2):673-685. PMC: 6994131. DOI: 10.1172/JCI130144. View

Porter D, Hwang W, Frey N, Lacey S, Shaw P, Loren A . Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015; 7(303):303ra139. PMC: 5909068. DOI: 10.1126/scitranslmed.aac5415. View

Rossi D, Sozzi E, Puma A, De Paoli L, Rasi S, Spina V . The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol. 2009; 146(1):64-75. DOI: 10.1111/j.1365-2141.2009.07711.x. View

Tinhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R . Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J Immunother. 2009; 32(3):302-9. DOI: 10.1097/CJI.0b013e318197b5e4. View

Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K . Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459. PMC: 6637939. DOI: 10.1056/NEJMoa1709919. View

Cappell K, Sherry R, Yang J, Goff S, Vanasse D, McIntyre L . Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2020; 38(32):3805-3815. PMC: 7655016. DOI: 10.1200/JCO.20.01467. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

10.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

11.

Riches J, Davies J, McClanahan F, Fatah R, Iqbal S, Agrawal S . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2012; 121(9):1612-21. PMC: 3587324. DOI: 10.1182/blood-2012-09-457531. View

12.

Frey N, Gill S, Hexner E, Schuster S, Nasta S, Loren A . Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2020; 38(25):2862-2871. PMC: 8265376. DOI: 10.1200/JCO.19.03237. View

13.

Hudecek M, Schmitt T, Baskar S, Lupo-Stanghellini M, Nishida T, Yamamoto T . The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-41. PMC: 2996114. DOI: 10.1182/blood-2010-05-283309. View

14.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

15.

Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X . Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front Immunol. 2019; 10:2664. PMC: 6863137. DOI: 10.3389/fimmu.2019.02664. View

16.

Shah N, Johnson B, Schneider D, Zhu F, Szabo A, Keever-Taylor C . Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020; 26(10):1569-1575. DOI: 10.1038/s41591-020-1081-3. View

17.

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

18.

Wieczorek A, Uharek L . Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother. 2014; 40(6):388-402. PMC: 3901623. DOI: 10.1159/000357163. View

19.

Milone M, Fish J, Carpenito C, Carroll R, Binder G, Teachey D . Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17(8):1453-64. PMC: 2805264. DOI: 10.1038/mt.2009.83. View

20.

Turtle C, Hay K, Hanafi L, Li D, Cherian S, Chen X . Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol. 2017; 35(26):3010-3020. PMC: 5590803. DOI: 10.1200/JCO.2017.72.8519. View